NASDAQ$MLTX
MoonLake Immunotherapeutics · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
MoonLake Immunotherapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting advancements in clinical trials and a strong cash position.
MoonLake Immunotherapeutics reported a net loss of $46.39 million for Q4 2024, with research and development expenses increasing to $40.36 million and general and administrative expenses rising to $9.22 million. The company maintained a strong cash position of $448.0 million, providing a runway until at least the end of 2026.
- Initiated Phase 3 VELA program for hidradenitis suppurativa (HS) and Phase 3 IZAR program for psoriatic arthritis (PsA) following positive regulatory feedback.
- Launched three new trials in early 2025: Phase 3 VELA-TEEN for adolescent HS, Phase 2 LEDA for palmoplantar pustulosis (PPP), and Phase 2 S-OLARIS for axial spondyloarthritis (axSpA).
- Signed a three-year technology partnership with Komodo Health to advance research using real-world data.
- Ended the year with $448.0 million in cash, cash equivalents, and short-term marketable debt securities, expected to fund operations until at least the end of 2026.
Headline financials
Revenue & EPS history
MoonLake · Revenue · Quarterly
$0
Forward guidance
MoonLake Immunotherapeutics anticipates a data-rich 2025 with pivotal HS data expected mid-year, focusing on commercialization efforts and continued clinical trial advancements.
Tailwinds
- Pivotal HS data expected as of mid-2025, positioning the company for potential commercialization.
- Seven ongoing Phase 2 and Phase 3 trials, plus other ancillary trials, indicate a robust clinical pipeline.
- Strong cash runway until at least the end of 2026, supporting future catalysts.
- Continued focus on cost control for shareholders.
- Upcoming in-person and virtual Capital Markets Update in Q2 2025 to provide further updates.
Headwinds
- No specific negative forward guidance was provided in the report.
- The company acknowledges inherent uncertainties and risks associated with clinical trials and drug development.
- Difficulty enrolling patients in clinical trials could impact timelines.
- State and federal healthcare reform measures could reduce demand for product candidates.
- Reliance on third parties to conduct and support preclinical studies and clinical trials poses risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2024
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+23.1%
Q2 2022
Best reaction
-10.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -2.9% | -4.8% | |
| Q3 2025 | -2.8% | +11.0% | +40.7% | |
| Q1 2025 | +4.7% | -2.2% | +14.8% | |
| Q4 2024 | -4.5% | -2.5% | -2.1% | |
| Q3 2024 | +0.6% | +0.8% | +5.5% | |
| Q1 2024 | -4.2% | -8.1% | -4.7% | |
| Q4 2023 | -10.4% | -15.3% | -11.6% | |
| Q3 2023 | +7.1% | +16.6% | +57.3% | |
| Q2 2023 | +3.5% | +3.8% | -5.7% | |
| Q1 2023 | +0.2% | +5.5% | +9.6% | |
| Q4 2022 | -4.9% | -9.2% | -5.6% | |
| Q3 2022 | -0.1% | -5.4% | +4.0% | |
| Q2 2022 | +23.1% | +45.8% | +33.0% | |
| Q1 2022 | -6.1% | +4.3% | +2.6% | |
| Q2 2021 | -0.1% | +0.0% | -0.1% | |
| Q4 2021 | -0.1% | +0.0% | -0.1% | |
| Q3 2021 | -1.3% | -1.3% | -1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro